aspiration (FNA) in any child with a concerning clinical history (ie, history of radiation, young age or genetic tumour syndrome) or whose nodules have suspicious ultrasound (US) findings.
12 Surgical intervention is also recommended for any child whose thyroid nodule is growing or has indeterminate cytology, given the higher likelihood of malignancy in children.
Despite these guidelines, challenges in the evaluation and management of paediatric thyroid nodules remain. First, while FNA is essential to accurately diagnose most thyroid nodules, obtaining the FNA in paediatric patients may be cumbersome. In general, FNA is a safe and low-risk paediatric procedure. However, performing the FNA in a child may require sedation: incurring additional time, cost and potential psychological stress for patients and their families.
Secondly, though US features suspicious for malignancy are well known to be similar between children and adults, few large studies explore which subtle, paediatric-specific US findings most predict malignancy. 4, 5 Finally, no well-validated paediatric scoring scheme helping predict malignancy risk, akin to the ATA Adult US Risk Stratification Scheme or the Adult McGill Thyroid Nodule Score, exists. 13, 14 Having an adjunctive scoring tool to be used with FNA results may help providers improve both the diagnosis and management of paediatric thyroid nodules.
Recent work has been done to identify potential thyroid nodule scoring tools suitable for paediatrics. In three independent paediatric cohorts, the Adult ATA Risk Stratification system (using specific ultrasound features to stratify malignancy risk) performed well, having a similar diagnostic accuracy for detecting malignancy in paediatric patients compared to adults. [15] [16] [17] The McGill Criteria is another thyroid nodule scoring system that uses ultrasound features, clinical findings and cytology results to predict malignancy risk. While many components of the McGill score likely predict malignancy risk for children and adults, some features such as nodule size or shape may not predict malignancy in children. 12 However, Canfarotta et al adapted the adult McGill Criteria for paediatric use (deleting factors such as age >45, PET scan results, serum thyroglobulin levels and mutations associated with adult malignancies) and described good diagnostic accuracy of the PMTNS in a pilot cohort of 46 children presenting with thyroid nodules despite keeping all of the adult-derived ultrasound components of the original tool.
6,14
Our aim was to determine the diagnostic accuracy of the Pediatric McGill Thyroid Nodule Score (PMTNS) in a large paediatric cohort and assess the accuracy of the sub-components of the score for predicting malignancy in children.
| ME THODS

| Study design and setting
We utilized an established retrospective cohort identifying paediatric patients (≤21 years) who presented to a single-institution, tertiary care children's centre with a thyroid nodule between 1996 and 2015.
The Mayo Clinic Institutional Review Board approved this study.
| Subjects
Approximately 330 patients presented with nodules during the study period. We chose to study patients ≤21 years of age, as this was felt to best represent a typical paediatric sub-specialty practice and increase the sample size to allow better comparisons between younger and older adolescent patients. To be included, patients needed to have an initial US and FNA performed at Mayo Clinic followed by either (a) histopathology results after thyroidectomy (b) a follow-up FNA performed at our institution ≥1 year after initial biopsy (c) a stable follow-up US performed at our institution ≥1 year after initial biopsy. In order to explore the score's performance in otherwise healthy patients presenting with thyroid nodules, we excluded patients with a genetic syndrome or a history of radiation exposure. All patients had available thyroid function tests at the time of diagnosis as well as ultrasound imaging and cytology results. In the minority of patients with multiple thyroid nodules, only the patient's two largest nodules were included in an attempt to reduce any statistical clustering effect. Our final cohort included 131 thyroid nodules from 99 patients.
| Definitions
We calculated the PMTNS for our cohort of otherwise healthy children ( Table 1) . The clinical components of the score were abstracted from the medical record. The physical examination features were derived from the first physical performed by a paediatric endocrinologist at our institution. A positive family history was defined as any first degree relative noted to have thyroid cancer.
The documented physical examination findings always noted the presence or absence of a palpable nodule; we categorized nodule consistency as not "bone hard" unless the terms "bone hard," "very hard," "extremely firm" were used in provider documentation. We chose to use the TSH level performed at our institution nearest the time of the initial US and FNA. All cytology reports were reviewed.
For reports before 2007, prior to when the Bethesda system was formalized, a Bethesda score was assigned based upon detailed pathology reports. The ultrasound and cytology features were recorded as described below. Any nodule ≥0.5 cm was included in our analysis. Each nodule was ultimately assigned one composite score, adding up the clinical, ultrasound and cytology sub-scores.
| Ultrasonography
Two paediatric radiologists with extensive experience, blinded to the previous radiology reads, cytology and/or histology results independently described multiple features. Diagnostic grey-scale US with colour Doppler was obtained using high-frequency linear array transducers with both cine imaging and still imaging using longitudinal and transverse views. All imaging was viewed on a singular image system and no nodules needed to be excluded due to poor image quality. In all patients, cervical lymph nodes were briefly eval- 
| Cytology and histology
Institutional radiologists performed FNA by free-hand technique with US guidance. Cytology results were reported using the Bethesda I System for reporting thyroid cytology. 18 This includes (I) TA B L E 1 (Continued)
non-diagnostic, (II) benign, (III) atypia of undetermined significance, (IV) suspicious for follicular neoplasm, (V) suspicious for malignancy and (VI) malignant categories. When a child's cytology did not require thyroidectomy, appropriate follow-up with either repeat FNA or repeat US ≥1 year was used to ensure the nodule was accurately classified as benign. 
| Statistical analysis
| RE SULTS
The overall malignancy rate was 33% (33/99 patients) ( Table 2 ).
In subsets of patients ≤17 and ≤12 years, the overall malignancy rate was similar at 29% (20/69) and 33% (6/18), respectively. The entire cohort was mostly adolescents (average age at diagnosis 15.4 ± 3.8 years). There was no statistically significant difference in age between patients with benign thyroid nodules (average age 15.3 ± 3.8 years) versus malignant nodules (average age 16.2 ± 3.7 years), P = 0.26. On average, 34% of patients had more than one nodule at the time of the first ultrasound at our institution with no significant difference between patients presenting with benign and malignant nodules (P = 0.71). The cohort was predominantly female (84%) with sex being equally distributed in those with benign (85%) and malignant (82%) nodules.
Most patients had a palpable nodule at initial presentation with no significant difference between those with benign and malignant nodules (82% vs 70%, respectively; P = 0.29). There was also no difference in initial TSH level (using the McGill recommended cut-off > 1.4 mIU/L) between patients with benign (45% TSH > 1.4 mIU/L) and malignant nodules (55% TSH > 1.4 mIU/L), P = 0.52. However, when a higher TSH cut-off was analysed (>2.9 mIU/L), there was a significant difference between patients with benign (11% TSH > 2.9 mIU/L) and malignant nodules (33% TSH > 2.9 mIU/L), P = 0.02. Although we excluded patients having a known genetic syndrome associated with thyroid cancer, 13% of patients (13/99) had a family history of thyroid cancer.
The per cent of patients with a family history of thyroid cancer was nearly identical between groups (14% and 12% respectively;
The total PMTNS average score for malignant nodules (12.7 ± 4.3) was higher than the total PMTNS average score for benign nodules (1.7 ± 2.9). The average PMTNS for nodules classified as Bethesda III (n = 2) was 7.5. A PMTNS ≥9 had a 90.9% sensitivity and 96.6% specificity for detecting thyroid cancer (Figure 1 ). A PMTNS ≥8 had a 93.2% sensitivity and 93.1% specificity for detecting thyroid cancer. In a subset analysis of patients ≤17 years (n = 69), the diagnostic accuracy was mildly reduced with PMTNS ≥8 having a 76.0% sensitivity and 95.5% specificity. In the small subset of children ≤12 years (n = 18) in our cohort, the diagnostic accuracy decreased with PMTNS ≥8 having a 57.1% sensitivity and 93.8% specificity. The diagnostic accuracy of the individual PMTNS sub-score components was explored (Table 3 ). In this cohort of otherwise healthy children presenting with a thyroid nodule, having a clinical subscore ≥1, 2 or 3 resulted in a specificity of 42.5%, 85.1% and 88.5%, 
TA B L E 2 Characteristics of patients with thyroid nodules
respectively, for detecting malignancy (OR 1.06-0.77). However, the sensitivity of the clinical sub-scores remained poor with a clinical sub
| D ISCUSS I ON
The overall thyroid nodule malignancy rate in our cohort (33%) is very similar to previous reports. 9, 16, 19 Our malignancy rate is likely inflated due to the study design, requiring at least one year of follow-up, therefore excluding patients more likely to have benign nodules. In this cohort of patients with a high malignancy rate, The
Pediatric McGill Thyroid Nodule Score (PMTNS) predicted malignancy well (sensitivity 93.2% and specificity 93.1%) in patients ≤21 years. However, though our sample size of young children is limited, the PMTNS declined in diagnostic accuracy when used in younger patients with a 76% sensitivity in patients ≤17 years (n = 69) and a 57% sensitivity in patients ≤12 years old (n = 18).
It is possible, given the PMTNS includes ultrasound components known to best predict malignancy risk in adults that the PMTNS performs better in older adolescents rather than in young children.
The better performance of the PMNTS in older adolescents compared with younger children is likely due to the fact that the score includes ultrasound components known to predict malignancy in adults, some of which are less relevant in younger children (eg, nodule size or shape). The only age used in the original MTNS is 45 years; based on the graded performance of the modified tool in 
TA B L E 3 Pediatric McGill Thyroid
Nodule Score components and relationship to malignancy detection our cohort, it would be useful to explore if the accuracy of the tool is also lower in a younger (18-25 years) versus older adult cohort.
Ultimately, our study suggests better PMTNS diagnostic performance in older rather than younger children. were lower in our study, the difference in scores between malignant and benign nodules, as well as the standard deviation of the scores in the malignant and benign groups, was very similar between studies.
Ongoing work is needed to determine the best PMTNS score cut-off points for optimal diagnostic performance across diverse paediatric populations and ages.
While the PMTNS incorporates clinical, ultrasound and cytology
features, adding these comprehensive features did not confer improvement to the diagnostic accuracy of cytology alone. The overall PMTNS predicted malignancy well, but the cytology sub-score independently had greater sensitivity (97.7%) and specificity (94.0%) for detecting thyroid cancer than the PMTNS. The cytology sub-score diagnostic accuracy, unlike the total PMTNS, did not decline in accuracy in younger patients (sensitivity 100% in children ≤17 years and children ≤12 years). Therefore, when cytology is available, it is likely to be the most useful means to predict malignancy. However, on occasion cytology results are limited or unclear. Though few patients in our cohort had nodules with Bethesda III cytology 2/131 (1.5%), the PMTNS may be helpful for children whose nodules have indeterminate cytology, similar to adults. 20 Secondly, the PMTNS may 
| Clinical features
The clinical sub-score was not sensitive for detecting thyroid cancer using any cut point in this sample of patients without known risk factors for thyroid cancer. However, a score ≥2 had good specificity for detecting thyroid cancer (85.1%) though the sensitivity was poor (22.7%). Clinical characteristics, including age, sex, nodule size or family history of thyroid malignancy, were not significantly different between patients with benign and malignant nodules. Interestingly, even in younger patients (≤12 years), the malignancy rate (33%) was no different compared to the entire cohort (33%). While young age is associated with a higher chance of persistent disease or recurrence, we did not find it affected the likelihood of malignancy, though it is thought that young children overall may have worse outcomes compared to adolescents given the same cancer burden.
12,21
Lastly, we had nearly a 5:1 female predominance, similar to previous studies. 9, 22, 23 We did find a significant difference in TSH levels between patients with malignant and benign nodules. The PMTNS employs a cut-off 
24-26
This potential relationship is thought to be related to the presence of chronic thyroid autoimmunity causing tissue damage, increasing cancer risk. TSH values in the upper end of normal may also be linked to paediatric malignancy, though a large study in children with previous thyroid autoimmunity did not find any association with malignancy and impaired thyroid function. 6, 12, 27 Authors did not examine TSH levels that were normal, but in the upper end of normal, and many children were already on thyroid supplementation, perhaps explaining the lack of association. 6 Exploring the relationship between thyroid autoimmunity and malignancy would be helpful, but often, these data are not available in retrospective reviews. In our study, the presence or absence of thyroid autoimmunity was not always available.
| Ultrasound findings
The ultrasound sub-score had a reasonable sensitivity (93.2% for a score ≥2) for detecting malignancy, but the specificity remained poor (42.4% for a score ≥2). Other ultrasound-based scoring systems, such as the American Thyroid Association Ultrasound Risk Stratification, perform similarly with a 91% sensitivity and 54% specificity for detecting thyroid cancer. 17 Many US features used in the adult and paediatric MTNS have been previously reported to be associated with thyroid cancer in children. For example, the presence of calcifications, whether coarse or micro calcifications, continues to be an US feature consistently associated with malignancy.
11,28
Hypoechogenicity and vascularity have also been linked to malignancy risk. 19, [29] [30] [31] Likewise, suspicious lymph node involvement highly predicted malignancy. 7, 10, 19, 29, 32, 33 In our cohort, 21% of malignant nodules were <1 cm. While the PMTNS includes nodule size as part of the scoring criteria, size of paediatric nodules is less predictive of malignancy in children and the American Thyroid Association Pediatric Guidelines currently suggest FNA of nodules with concerning features even if they are <1 cm in diameter. 
| Limitations
Our data and conclusions should be viewed in the context of several limitations. First, while we identified 330 patients presenting with thyroid nodules, a large number of patients had to be excluded as they did not have at least one year of follow-up at our institution. By this intentional study design, we selected against patients with benign thyroid nodules who elected to pursue care closer to home. We also acknowledge that our cohort likely had a strong referral bias, being a tertiary centre and patients presenting for care may be more likely to have cancer and advanced disease.
Studying the PMTNS in a cohort with a high malignancy rate may have impacted the tool's performance. We also chose to exclude children with a history of radiation or genetic tumour syndromes.
Doing so may also have impacted the PMTNS performance and certainly reduces the generalizability of our findings to these specific patient populations. Lastly, we had the benefit of experienced pathologists and a very low rate of indeterminate cytology results.
In particular, we only had five non-diagnostic and two indeterminate cytology samples. It is possible that there may be further value in the PMTNS if more non-diagnostic or indeterminate cytology results were present.
| CON CLUS ION
We found a Pediatric McGill Thyroid Nodule Score ≥8 optimized the diagnostic performance in our cohort with a 93.2% sensitivity and 93.1% specificity in patients ≤21 years old. However, the Pediatric McGill Thyroid Nodule Score had diminishing accuracy when used in younger children with a sensitivity of 76% in patients ≤17 years (n = 69) and 57% in patients ≤12 years old (n = 18).
Cytology results alone performed well across all age groups and predicted malignancy better than the Pediatric McGill Thyroid
Nodule Score (sensitivity 98%-100% across age groups). Our cohort had a high malignancy rate, and we also excluded children with known risk factors for thyroid cancer: Both of these fac- Score may be useful with good sensitivity, but poorer specificity
